The Bax24 trial was a randomized, double-blind, placebo-controlled, phase 3 study that enrolled 218 patients with resistant hypertension, defined as high blood pressure despite the use of at least three antihypertensive medications, including a diuretic.[1][2][3] Patients were randomly assigned to baxdrostat 2 mg once daily or placebo for 12 weeks in addition to standard treatment.[1][2][3] The primary endpoint was change in 24-hour mean ambulatory systolic blood pressure (SBP) from baseline to week 12.[2][3] Baxdrostat reduced this parameter by 14 mmHg more than placebo.[2] A greater proportion of patients on baxdrostat achieved a target 24-hour SBP below 130 mmHg (70.6% vs. 16.7% in the placebo group).[2] The effect was consistent throughout the day, including the morning surge.[3] The drug was generally well tolerated with a safety profile similar to the BaxHTN trial.[1][2]